We are live on ! Find out more
UTMD icon

Utah Medical Products

119 hedge funds and large institutions have $140M invested in Utah Medical Products in 2026 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 48 increasing their positions, 29 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

66% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 29

44% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 9

20% more capital invested

Capital invested by funds: $118M → $140M (+$23M)

5.2% more ownership

Funds ownership: 65.54%70.74% (+5.2%)

2% more funds holding

Funds holding: 117119 (+2)

0% more funds holding in top 10

Funds holding in top 10: 11 (0)

Holders
119
Holders Change
+2
Holders Change %
+1.71%
% of All Funds
1.46%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.01%
New
13
Increased
48
Reduced
29
Closed
9
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
BIP
1
Brandes Investment Partners
California
$27.9M +$6.17M +97,957 +28%
Dimensional Fund Advisors
2
Dimensional Fund Advisors
Texas
$12.3M +$88.1K +1,399 +0.7%
BlackRock
3
BlackRock
New York
$11.6M +$196K +3,112 +2%
Renaissance Technologies
4
Renaissance Technologies
New York
$11.4M -$598K -9,500 -5%
VCM
5
Vanguard Capital Management
Pennsylvania
$8.59M +$8.73M +138,560 New
Geode Capital Management
6
Geode Capital Management
Massachusetts
$7.45M +$2.04M +32,302 +37%
MA
7
Minerva Advisors
Pennsylvania
$5.8M
Hotchkis & Wiley Capital Management
8
Hotchkis & Wiley Capital Management
California
$5.53M -$1.25M -19,870 -18%
RHJA
9
Rice Hall James & Associates
California
$4.21M +$219K +3,484 +5%
State Street
10
State Street
Massachusetts
$4.01M -$227K -3,605 -5%
Morgan Stanley
11
Morgan Stanley
New York
$3.03M +$321K +5,096 +12%
UBS Group
12
UBS Group
Switzerland
$2.29M +$2.31M +36,602 +11,657%
HCM
13
Huber Capital Management
California
$2.23M -$58.3K -925 -3%
Bank of New York Mellon
14
Bank of New York Mellon
New York
$1.99M -$218K -3,457 -10%
Northern Trust
15
Northern Trust
Illinois
$1.88M +$63.9K +1,015 +3%
QCM
16
Quantinno Capital Management
New York
$1.85M +$387K +6,146 +26%
CCMINC
17
Cardinal Capital Management Inc (North Carolina)
North Carolina
$1.65M +$108K +1,707 +7%
EHC
18
Everett Harris & Co
California
$1.58M +$266K +4,220 +20%
SBH
19
Segall Bryant & Hamill
Illinois
$1.34M +$634K +10,065 +88%
OSAM
20
O'Shaughnessy Asset Management
Connecticut
$1.32M +$402K +6,384 +43%
LSV Asset Management
21
LSV Asset Management
Illinois
$1.23M +$402K +6,385 +47%
VFT
22
Vanguard Fiduciary Trust
Pennsylvania
$1.18M +$1.2M +19,056 New
BA
23
Bard Associates
Illinois
$1.14M +$10.1K +161 +0.9%
T. Rowe Price Associates
24
T. Rowe Price Associates
Maryland
$1.14M +$228K +3,620 +25%
Fidelity Investments
25
Fidelity Investments
Massachusetts
$1.12M +$304K +4,822 +36%

UTMD Hedge Fund Activity: Q1 2026 in Review

119 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Utah Medical Products (UTMD) for Q1 2026, worth a combined $140M — up 20% from $118M a quarter earlier.

Buyers outnumbered sellers: 13 funds opened new UTMD positions and 9 closed out — a net gain of 4 holders — while 48 added to existing stakes and 29 trimmed.

The largest buyer was Brandes Investment Partners, adding an estimated $6.17M. The largest seller was Hotchkis & Wiley Capital Management, cutting an estimated $1.25M.

  • 119 institutional investors held Utah Medical Products (UTMD) as of Q1 2026, up from 117 in Q4 2025.
  • Funds reported $140M of Utah Medical Products stock for Q1 2026, up 20% quarter-over-quarter.
  • 13 funds opened new Utah Medical Products positions in Q1 2026 and 9 closed out, a net change of +4 holders.
  • The largest Utah Medical Products buyer in Q1 2026 was Brandes Investment Partners, an estimated $6.17M added.
  • The largest Utah Medical Products seller in Q1 2026 was Hotchkis & Wiley Capital Management, an estimated $1.25M sold.

Based on aggregated 13F filings for Q1 2026.